ArticleThe Lancet. Respiratory medicine2026

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.

David E Gerber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.